Arvinas (ARVN) Total Liabilities (2017 - 2026)
Arvinas (ARVN) recorded quarterly Total Liabilities of $260.7 million in Q1 2026, down 8.2% quarter-over-quarter from $284.0 million in Q4 2025, and down 23.55% on a YoY basis from $341.0 million in Q1 2025.
Arvinas (ARVN) Total Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Liabilities history runs 10 years deep, the most recent figure standing at $260.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 23.55% year-over-year to $260.7 million; the TTM figure through Mar 2026 stood at $260.7 million (down 23.55% YoY), while the FY2025 annual figure was $284.0 million, down 46.38% from the prior year.
- Total Liabilities was $260.7 million for Q1 2026 at Arvinas, down from $284.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $765.0 million in Q1 2022 to a low of $260.7 million in Q1 2026.
- Historically, Total Liabilities has averaged $547.5 million across 5 years, with a median of $602.9 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 1105.64% in 2022, then plunged 55.84% in 2025.
- A 5-year view of Total Liabilities shows it stood at $703.9 million in 2022, then dropped by 8.42% to $644.6 million in 2023, then retreated by 17.83% to $529.7 million in 2024, then slumped by 46.38% to $284.0 million in 2025, then fell by 8.2% to $260.7 million in 2026.
- The last three Total Liabilities figures came in at $260.7 million (Q1 2026), $284.0 million (Q4 2025), and $279.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 10.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 19.51 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 137.56 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 260.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 260.70 Mn |
| Dec 31, 2025 | 284.00 Mn |
| Sep 30, 2025 | 279.90 Mn |
| Jun 30, 2025 | 300.00 Mn |
| Mar 31, 2025 | 341.00 Mn |
| Dec 31, 2024 | 529.70 Mn |
| Sep 30, 2024 | 581.10 Mn |
| Jun 30, 2024 | 679.40 Mn |
| Mar 31, 2024 | 602.90 Mn |
| Dec 31, 2023 | 644.60 Mn |
| Sep 30, 2023 | 601.10 Mn |
| Jun 30, 2023 | 619.90 Mn |
| Mar 31, 2023 | 664.80 Mn |
| Dec 31, 2022 | 703.90 Mn |
| Sep 30, 2022 | 713.30 Mn |
| Jun 30, 2022 | 736.40 Mn |
| Mar 31, 2022 | 765.00 Mn |
| Dec 31, 2021 | 799.90 Mn |
| Sep 30, 2021 | 787.13 Mn |
| Jun 30, 2021 | 61.08 Mn |